ASCO 2015 Highlights

Erlotinib Plus Bevacizumab as First-Line Treatment for EGFR+, Advanced NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Adjuvant Ipilimumab for Patients with High-Risk Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

First Trial Assessing Nivolumab in Platinum-Resistant Ovarian Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Phase 2 Trial of Nivolumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Phase 2 Trial of Nivolumab and VEGF Inhibitors in First-Line Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

MPDL3280A, an Anti-PD-L1 Monoclonal Antibody, in Metastatic Bladder Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Chemotherapy Plus Bevacizumab or Cetuximab in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Racial Differences in KRAS/BRAF Mutation Rates and Survival in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Pharmacokinetics of MEDI4736, an Anti-PD-L1 Monoclonal Antibody, in Advanced Solid Tumors

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Early Predictors of Overall Survival in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Page 228 of 330